The Microbiome-Bile Acid-Immune Axis in the Era of Emerging Therapies for Primary Biliary Cholangitis
Year: 2026
Type: preprint
Abstract: Primary biliary cholangitis (PBC) is a chronic immune-mediated cholestatic liver disease in which interactions among the intestinal microbiome, bile acid metabolism, and immune regulation may influence disease pathogenesis, progression, and therapeutic response. This narrative review synthesizes clinical and experimental evidence concerning the microbiome-bile acid-immune axis and its relevance to emerging therapeutic strategies. Studies involving patients with PBC have identified alterations in intestinal microbial composition and diversity, disturbances in bile acid profiles, and microbial signatures associated with biochemical response to ursodeoxycholic acid. Microbiome-derived metabolites, including short-chain fatty acids, secondary bile acids, and tryptophan derivatives, may influence intestinal barrier integrity, bile acid receptor signaling, and innate and adaptive immune responses. However, much of the mechanistic evidence originates from experimental models or other liver and immune-mediated diseases, and causal relationships in human PBC remain incompletely established. Emerging peroxisome proliferator-activated receptor agonists, particularly elafibranor and seladelpar, have demonstrated biochemical efficacy, while the potential contribution of microbiome-mediated mechanisms to their therapeutic effects remains uncertain. Microbiome-directed interventions, including probiotics and fecal microbiota transplantation, remain investigational in PBC. Longitudinal multi-omics investigations, functional studies, and prospective biomarker validation are essential to establish clinically relevant mechanisms and evaluate opportunities for more personalized therapeutic approaches.
Source: Preprints.org
Language: English
Topic: Liver Diseases and Immunity
Subfield: Hepatology
Field: Medicine
Domain: Health Sciences
Keywords: primary biliary cirrhosis, gut microbiota, bile acid metabolism, ursodeoxycholic acid response, short-chain fatty acids, secondary bile acids, tryptophan metabolites, intestinal barrier integrity, innate and adaptive immunity, peroxisome proliferator-activated receptor agonists, elafibranor, seladelpar, probiotics, fecal microbiota transplantation, cholestatic liver disease
Open Access status: green
OpenAlex ID: W7226001602
